The federal government will place RSV vaccines on the national immunisation program, as 12,000 babies are hospitalised with ...

Nationwide RSV immunisation program to keep 10,000 babies out of hospitalImmunisation advocates are heralding the Albanese Government's commitment to ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

At the ITF Masters event in Bedford, NS, last month, the Canadians cleaned up by winning almost every title at the Atlantic Masters.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

The vaccine for this population is usually ABRYSVO. “Science supports this vaccine, as significantly decreasing the infant or neonate’s likelihood of developing a severe lower respiratory tract ...